An Introduction to the Stem Cell Niche: What is it, Really?

Stem cell populations in the body live in stem cell niches, each different type of stem cell with its own niche. The niche supplies the necessary environment and many of the cues that direct stem cell activity, and this is why changes in the niche are possibly more important than changes in stem cells themselves when it comes to the decline of stem cell activity with aging. That decline causes a sort of corrosion of your tissues as stem cells increasingly fail to keep up with maintenance and repair - but the evidence to date suggests that those stem cells are generally still capable of doing their jobs, provided they are given their marching orders:

Surprisingly, this age-related decline in stem cell potency may be somewhat reversible. A team of Howard Hughes Medical Institute (HHMI) researchers has found that in old mice, a several-week exposure to the blood of young mice causes their bone marrow stem cells to act "young" again. ... The researchers have not yet isolated the blood-borne factors that can switch old stem cells back to a more youthful state, but their results are consistent with other recent studies that show stem-cell aging may be reversible.

Thus we have to look at the aging of stem cells in the context of the niche and the rest of the body, and we have to look at regenerative medicine for the old in a holistic way. While throwing stem cells at every problem seems to be fairly beneficial, based on the successes to date in first generation stem cell transplant therapies, it isn't enough in and of itself. Putting good stem cells into an age-damaged environment is not using them to their best effect.

But this all comes back to the question of just what a stem cell niche is anyway, and why the changes of aging change the way in which stem cells act within the body. Here is a good open access paper that provides an introduction to the niche and its importance, with some examples of various different stem cell and niche types throughout the body:

What does the concept of the stem cell niche really mean today?

Ideas about stem cells, and how they behave, have been undergoing a lot of change in recent years, thanks to developments in visualizing, monitoring, and manipulating cells and tissues. ... the detailed mechanisms underlying niche function are extremely varied. Niches may be composed of cells, or cells together with extracellular structures such as the extracellular matrix (ECM). They may be sources of secreted or cell surface factors [that] control stem cell renewal, maintenance, or survival. They may consist of just a single cell type, or a whole host of interacting cells. They may derive from cells outside the stem cell's lineage, or they may derive primarily from the stem cell's own descendents. In general, there seems to be much more consensus about the fact that stem cells invariably need niches than about the specific mechanisms by which niches do their jobs.

Why should a stem cell need a special environment? This is a pertinent question, given that none of the elementary processes that stem cells rely upon - growing, dividing, differentiating - are unique to stem cells. We can easily imagine three classes of answers:

One possibility is that there are demands placed on stem cells that necessitate special support for viability. For example, the need, imposed by cellular immortality, to minimize the accumulation of genetic damage, may drive stem cells to adopt a peculiar metabolic state that might force them to rely upon other cells nearby for sustenance. This 'nutritive' function of the niche remains a formal possibility, but in most systems few experimental data in support of it have so far emerged.

A second possibility is that niches are agents of feedback control. Recent studies tell us that stem cell pools are not slavishly maintained at a constant size by fixed, asymmetric divisions, but are usually capable of expanding or contracting and, even under homeostatic conditions, may face large stochastic fluctuations. The varied growth factors and cell surface molecules produced by niche cells may share the common goal of controlling stem cell pools. If this is the case, then the niche might best be thought of not simply as an environment conducive to stem cell functioning, but as an apparatus for communicating information about the state of a tissue back to the stem cells that maintain it. An important question to address would then be how niches obtain and relay such information.

A third possibility is that niches are instruments of coordination among tissue compartments. Some of the best evidence for this view comes from work on the hair follicle niche ... There, stem and progenitor cells responsible for maintenance of epidermis, pigmentation, hair, and connective and adipose tissue all interact in close proximity. A need to achieve tight coordination among these different cell populations may be the overriding reason for complex organization of this niche. The possibility that other niches may also be hubs of inter-lineage coordination is certainly an idea worth investigating.

The best case scenario for the future is that enacting the Strategies for Engineered Negligible Senescence to repair the known forms of cellular and molecular damage that occur with aging will cause stem cell niches to largely take care of themselves. In other words, under this scenario it turns out that the second possibility outlined in the quote above is the principal role for niches, and thus repairing the biological damage of aging in the body will cause the command and control mechanisms for stem cell populations to return to a youthful state.

Source:
http://www.longevitymeme.org/newsletter/latest_rss_feed.cfm

Considering Bypassing the Electron Transport Chain in Damaged Mitochondria

Damaged mitochondria cause problems because their electron transport chains, the core mechanism by which they generate power for the cell, stop working the right way. That leads to a situation in which sub-par mitochondria in a cell are not recycled despite being damaged, and since they replicate like bacteria the bad mitochondria take over the cell. It goes downhill from there, and this whole process is one of the fundamental causes of aging. Ways of addressing this situation include repairing the mitochondria directly or working around their damage by creating replacements for the damaged parts of mitochondrial protein machinery elsewhere in the cell. Here is another line of research that looks at trying to minimize the consequences of that damaged machinery by providing substitute components, but with a different focus: "Mitochondrial dysfunction (primary or secondary) is detrimental to intermediary metabolism. Therapeutic strategies to treat/prevent mitochondrial dysfunction could be valuable for managing metabolic and age-related disorders. Here, we review strategies proposed to treat mitochondrial impairment. We then concentrate on redox-active agents, with mild-redox potential, who shuttle electrons among specific cytosolic or mitochondrial redox-centers. We propose that specific redox agents with mild redox potential improve mitochondrial function because they can readily donate or accept electrons in biological systems, thus they enhance metabolic activity and prevent reactive oxygen species (ROS) production. These agents are likely to lack toxic effects because they lack the risk of inhibiting electron transfer in redox centers. ... This view has been demonstrated by testing the effect of several redox active agents on cellular senescence. Methylene blue (MB) appears to readily cycle between the oxidized and reduced forms using specific mitochondrial and cytosolic redox centers. MB is most effective in delaying cell senescence and enhancing mitochondrial function in vivo and in vitro. Mild-redox agents can alter the biochemical activity of specific mitochondrial components, which then in response alters the expression of nuclear and mitochondrial genes. We present the concept of mitochondrial electron-carrier bypass as a potential result of mild-redox agents, a method to prevent ROS production, improve mitochondrial function, and delay cellular aging. Thus, mild-redox agents may prevent/delay mitochondria-driven disorders."

Link: http://www.ncbi.nlm.nih.gov/pubmed/22419586

Source:
http://www.longevitymeme.org/newsletter/latest_rss_feed.cfm

Exercising the Mind as a Basis for Therapy

Just as physical exercise is beneficial, so too is exercising the mind. This open access paper examines structured mental exercise as a basis for therapy that might do at least some good for neurodegenerative disease patients: "Non-pharmacological intervention of memory difficulties in healthy older adults, as well as those with brain damage and neurodegenerative disorders, has gained much attention in recent years. The two main reasons that explain this growing interest in memory rehabilitation are the limited efficacy of current drug therapies and the plasticity of the human central nervous system and the discovery that during aging, the connections in the brain are not fixed but retain the capacity to change with learning. Moreover, several studies have reported enhanced cognitive performance in patients with neurological disease, following non-invasive brain stimulation [i.e., repetitive transcranial magnetic stimulation and transcranial direct current stimulation to specific cortical areas]. The present review provides an overview of memory rehabilitation in individuals with mild cognitive impairment and in patients with Alzheimer's disease with particular regard to cognitive rehabilitation interventions focused on memory and non-invasive brain stimulation. Reviewed data suggest that in patients with memory deficits, memory intervention therapy could lead to performance improvements in memory, nevertheless further studies need to be conducted in order to establish the real value of this approach."

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3297818/

Source:
http://www.longevitymeme.org/newsletter/latest_rss_feed.cfm

Attempting to Address the Popular Myth of Antioxidants

The industry that provides antioxidant supplements to the world has tremendous inertia: enormous income and a very loud voice, and thus little incentive to react to advances in scientific knowledge that might reduce that revenue stream if acted upon. So despite the scientific consensus that ingested antioxidants are not in fact wonderful for your health, and may even be modestly harmful over the long term, the larger players in the industry continue onward as though it's still 1992 outside their offices.

On the other side of the fence, the public at large keeps buying the products as though it's still 1992, just as blithely ignoring what the scientific community has to say on the matter. Everyone wants that silver bullet to be available now rather than tomorrow, and wants it badly enough to buy lead painted up to a nice sheen if that's all there is. All in all it's a good reminder that any institutional knowledge or common wisdom is likely to be a decade or two out of date - it takes time for information to percolate, even in this age of instant electronic overcommunication. There is seemingly so much that everyone has to say, day in and day out, and yet the important data still takes years to get from point A to point B.

Here is a good open access paper on antioxidants and just how far removed from reality the common wisdom is these days. I imagine it will take a few more years of authoring similar review papers for the point to start to sink in:

Antioxidants are assumed to provide numerous benefits, including better health, a reduced rate of aging, and improved exercise performance. Specifically, antioxidants are commonly "prescribed" by the media, supplement industry, and "fitness experts" for individuals prior to training and performance, with assumed benefits of improved fatigue resistance and recovery. This has provoked expansion of the supplement industry which responded by creation of a plethora of products aimed at facilitating the needs of the active individual. However, what does the experimental evidence say about the efficacy of antioxidants on skeletal muscle function? Are antioxidants actually as beneficial as the general populous believes? Or, could they in fact lead to deleterious effects on skeletal muscle function and performance?

...

Experimental evidence does not support the "common knowledge" that antioxidant treatment greatly improves exercise performance and recovery. On the contrary, studies with antioxidant supplementations generally show no effect on muscle function during and after exercise.

Source:
http://www.longevitymeme.org/newsletter/latest_rss_feed.cfm

The Behavior of Fat Tissue With Calorie Restriction

Less fat tissue is unambiguously good for you over the long term, and one side effect of calorie restriction is the loss of excess fat tissue - but that is only a side effect. More interesting stuff is going on at the level of cells and their mechanisms: "Caloric restriction (CR) slows the aging process and extends longevity, but the exact underlying mechanisms remain debatable. It has recently been suggested that the beneficial action of CR may be mediated in part by adipose tissue remodeling. Mammals have two types of adipose tissue: white adipose tissue (WAT) and brown adipose tissue (BAT). In this study, proteome analysis [was] performed on both WAT and BAT from nine month old male rats fed ad libitum or subjected to CR for six months. Our findings suggest that CR activates mitochondrial energy metabolism and fatty acid biosynthesis in WAT. It is likely that in CR animals WAT functions as an energy transducer from glucose to energy-dense lipid. In contrast, in BAT CR either had no effect on, or down-regulated, the mitochondrial electron transport chain, but enhanced fatty acid biosynthesis. This suggests that in CR animals BAT may change its function from an energy consuming system to an energy reservoir system. Based on our findings, we conclude that WAT and BAT cooperate to use energy effectively via a differential response of mitochondrial function to CR." It is worth noting that there are other signs that the biochemistry of fat tissue, and its effects on health, can be dramatically altered - see the research on fat in GHRKO mice, for example.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22414572

Source:
http://www.longevitymeme.org/newsletter/latest_rss_feed.cfm

Another Run at Targeting RAGE

One of the underlying mechanisms by which the advanced glycation endproducts (AGEs) that build up with age cause harm is through hammering on the receptor for AGEs, or RAGE. Some Alzheimer's researchers are looking into targeting RAGE in order to remove the contribution of AGEs to that condition, and it is possible that the results of their work may have more general application to AGEs in aging - though the best possible strategy would be to remove the AGEs rather than work around them: "Researchers have taken another crack at a promising approach to stopping Alzheimer's disease that encountered a major hurdle last year. ... scientists have developed a compound that targets a molecular actor known as RAGE, which plays a central role in mucking up the brain tissue of people with the disease. Scientists [synthesized] a compound that stops RAGE in mice - reversing amyloid deposits, restoring healthy blood flow in the brain, squelching inflammation, and making old, sick mice smarter. But the scientists caution that the work has a long way to go before it's considered as a possible treatment in people. ... A phase 2 study in 399 people of another compound designed to stop RAGE - which stands for Receptor for Advanced Glycation Endproducts - was halted prematurely in November when scientists had questions about the compound's safety at high doses, and after early results indicated that the compound was not helping patients with Alzheimer's disease. ... The benefits of blocking RAGE are even greater than has been realized. RAGE is central to many mechanisms that wreak havoc in the brains of people with Alzheimer's disease. It turns out that when you inhibit RAGE, you block molecules central to creating inflammation in the brain, and that is a major problem with Alzheimer's disease."

Link: http://www.urmc.rochester.edu/news/story/index.cfm?id=3440

Source:
http://www.longevitymeme.org/newsletter/latest_rss_feed.cfm

SENS5 Video: Max More on the Necessity of Cryonics

A billion people will die between now and the earliest plausible date for the first package of rough and ready but working rejuvenation therapies - say twenty years from now. Another few decades will pass for the technology to work its way out to global availability at low cost, and the deaths by aging will continue in less fortunate regions while this happens. Even after aging is completely conquered, there will be an ongoing toll of death due to accidents and whatever passes for disease in the age of medical nanotechnology. Death isn't going away completely for we biological folk, no matter how well we do in the field of medicine in the foreseeable future: medicine can't wave away falling rocks.

Thus will always be a role for what we might term post-mortem critical care: technologies and services to preserve the fine structure of the brain and the mind it contains following death, and keep them preserved until such time as that patient can be restored to life. At present the only post-mortem critical care option is cryonics, with what looks like a fair few years to wait for technology to advance to the point of restoration, and thus an unknown chance of eventual success for any individual - but a significantly greater chance than is offered by the grave, of course. In contrast, in a future in which the technology to restore a preserved person exists, cryonics and other preservation technologies like plastination will occupy a more dynamic position in the medical toolkit, and patients might expect to wait in a preserved state only for transport to the nearest major population center.

At last year's SENS5 conference, Max More, CEO of cryonics company Alcor, gave this presentation on the future of his industry:

Cryonics involves the cryopreservation of humans as soon as possible after legal and clinical "death". Legal and clinical death differ importantly from biological death or true (irreversible) cessation of function. It is therefore a mistake to portray cryonics as an alternative to cremation or burial. It is true that cryopreserved people are not alive but neither are they dead. Cryonics should be seen as part of the field of life extension. Cryonics enables the transport of critically ill people through time in an unchanging state to a time when more advanced medical and repair technologies are available. Even after "longevity escape velocity" has been attained and aging has been largely tamed, cryonics will continue to be needed for people who die of accidents or diseases for which there is no cure at the time.

Source:
http://www.longevitymeme.org/newsletter/latest_rss_feed.cfm

Red Meat and Mortality Correlations

Here is a study claiming a noticeable impact on mortality rates from eating red meat. Weight is considered to some degree via body mass index, but I have to wonder if this only reflects a modest association of red meat consumption with other, less healthy lifestyle choices rather than an actual red-meat-based mechanism - as an obvious candidate mechanism for that isn't also present in all meat consumption isn't springing to mind: researchers "found that red meat consumption is associated with an increased risk of total, cardiovascular, and cancer mortality. The results also showed that substituting other healthy protein sources, such as fish, poultry, nuts, and legumes, was associated with a lower risk of mortality. ... [Researchers] observed 37,698 men from the Health Professionals Follow-up Study for up to 22 years and 83,644 women in the Nurses' Health Study for up to 28 years who were free of cardiovascular disease (CVD) and cancer at baseline. Diets were assessed through questionnaires every four years. ... One daily serving of unprocessed red meat (about the size of a deck of cards) was associated with a 13% increased risk of mortality, and one daily serving of processed red meat (one hot dog or two slices of bacon) was associated with a 20% increased risk. ... These analyses took into account chronic disease risk factors such as age, body mass index, physical activity, family history of heart disease, or major cancers. ... Replacing one serving of total red meat with one serving of a healthy protein source was associated with a lower mortality risk: 7% for fish, 14% for poultry, 19% for nuts, 10% for legumes, 10% for low-fat dairy products, and 14% for whole grains. The researchers estimated that 9.3% of deaths in men and 7.6% in women could have been prevented at the end of the follow-up if all the participants had consumed less than 0.5 servings per day of red meat."

Link: http://www.sciencedaily.com/releases/2012/03/120312162746.htm

Source:
http://www.longevitymeme.org/newsletter/latest_rss_feed.cfm

Producing Retinal Structures from Stem Cells

Via ScienceDaily: researchers "have made early retina structures containing proliferating neuroretinal progenitor cells using induced pluripotent stem (iPS) cells derived from human blood. And in another advance, the retina structures showed the capacity to form layers of cells - as the retina does in normal human development - and these cells possessed the machinery that could allow them to communicate information. ... Put together, these findings suggest that it is possible to assemble human retinal cells into more complex retinal tissues, all starting from a routine patient blood sample. Many applications of laboratory-built human retinal tissues can be envisioned, including using them to test drugs and study degenerative diseases of the retina such as retinitis pigmentosa, a prominent cause of blindness in children and young adults. One day, it may also be possible replace multiple layers of the retina in order to help patients with more widespread retinal damage. ... We don't know how far this technology will take us, but the fact that we are able to grow a rudimentary retina structure from a patient's blood cells is encouraging, not only because it confirms our earlier work using human skin cells, but also because blood as a starting source is convenient to obtain."

Link: http://www.sciencedaily.com/releases/2012/03/120313185232.htm

Source:
http://www.longevitymeme.org/newsletter/latest_rss_feed.cfm

SENS5 Video: Talking About Data Infrastructure

This is an era of data in the sciences - endless, vast stores of data, with more pouring in constantly from new studies. In most fields the infrastructure to manage that data is still under construction; in the life sciences, for example, the rapid advance of bioinformatics and biotechnology in general has outpaced the strategies for data management. The data infrastructure is lacking, even as it is being built up rapidly. This has consequences on the efficiency of research and the speed of progress, but researchers are not blind to this present state of affairs.

Here, for example, Maria Konovalenko of the Science for Life Extension Foundation presents at last year's SENS5 conference, calling for better and more systematic management of data in longevity research initiatives - which is effectively a form of advocacy for lowering the cost of exchange of information between research groups.

Traditionally evaluation of age-related changes is performed by physiological, functional and psychological tests, by visual examination and some biochemical analyses. There is a big gap between the molecular data of aging and their implementation in practice mainly because aging data is scarce and it gets lost in the stream of bio-medical knowledge. As we know only a few databases exist that concern the molecular aspects of aging and none of them describes age-related changes and phenotype context like cell type or tissues.

We propose creation of an open web-based Integrated Information System on Aging Biomarkers. The goals of the System: 1. Systematization of data on age-related changes happening on various levels of organization in humans and model animals 2. Systematization of experimantal data on interventions in aging processes in model animals 3. Integration of clinical data on the impact of various interventions on aging processes in patients 4. Creation of a basis for modeling of aging processes, therapeutic interventions and their impact on patients' health and longevity

When development of life extending therapies begins in any earnest way (as opposed the present expensive dabbling with metabolic manipulation to slightly slow aging), it will be necessary to start keeping score and measuring well. Even before then, and as I pointed out above, there is more data than can easily be made useful at this time - that has to change in order to build a better foundation for the next generation of research projects.

Source:
http://www.longevitymeme.org/newsletter/latest_rss_feed.cfm

Biotechnological applications boost Canada’s economic growth

Biotechnology, as the term indicates, is the technical use of living organisms and biological processes for obtaining bio products. These products are used in the field of medicine, agriculture and industries. Biotechnology has been used in various day to day processes since time immemorial. From preparation of wine, cheese, curing of tea leaves to natural manures and jute processing, the knowledge of biology has been put to effective use in the various spheres of our lives. With the advent of modern biotechnology in the 1980s, this field has seen a great boom in its totality. The first major footprint of this modern era is believed to have begun when the American Supreme Court granted patent to Ananda Chakraborty for the genetically modified Pseudomona species capable of breaking down crude oil. Ever since it has spread its root wide in every possible field. Hence, now it is being considered as a bright prospect for the future industries.

The statistics

Recently, the reports of a study on the economic viability of biotechnology, conducted by the Centre for the study of Living Standards (a nonprofit Canadian organization aimed at economic research), was published. It was based on the figures provided by the Statistics Canada’s Biotech Use and Development Survey (BUDS). The research was headed by economist Ricardo de Avellez. The study showed great promise in the field with a forecast of $144 billion industry by 2030 at an average growth rate of 9.4%. Canada, being the world’s 10th largest economy, though generates only 1.19% of the total economy GDP from the biotechnology industry, it has seen phenomenal GDP growth at 10.7% between 1999-2007 preceded only by the mining and oil and gas extraction industry at 20.5%. This shows the rich economical implications that this field awaits in the mere future. In 2005 the number of innovative biotech firms increased from 358 in 1999 to 532, almost a 50% growth. Besides the impressive GDP, the employment that the industry has generated around itself is also a boon. Around 13,500 employees were employed in the various firms in 2005, a 74% increase from the figures in 1999. This figure definitely points to the immense potential of this yet to be explored field.

Biotechnology started in three different waves in three different time periods but now they overlap:

1. The Green Wave-Agricultural Biotechnology

This has been there right from the cradle of ancient civilizations. Nowadays with the development of genetically modified crops better yielding, pest resistant, seed less crops are being yielded. Only 20.1% firms and 9.8% of the work force are involved in the agricultural biotechnology and it generates 24.6% of the total revenue. Surely this field has a greater potential and would play an important role in meeting the food demands of the future.

2. The Red Wave-Medical Biotechnology

This field has seen the greatest growth. 58.3% of the biotech companies were involved in the health care system. A majority of 80.9% employees lent their workforce and it generated 70.6% of the revenue. The obvious reasons for its growth are the vaccines, artificial hormones, diagnostic tests, genetically tailored medicine and the list goes on.

3. The White Wave, the most recent Industrial Biotechnology

It is particular to term this a virgin field as its potential has been put to use the least whereas this is the field which shows the greatest promise. From development of biomining to bioremediation, from biofuels to biosensors, this field is teeming with unexplored industrial potentialities. With a small amount of industries into it, the field actually has seen a 10.1% decline in its revenues.

The bottomline

Biotechnology will definitely play a significant role in the country’s economy as more industries based on it will come up. Also the need for sustainable systems and cleaner and greener technology will provide impetus to this versatile field. Combined with the rich abundant natural resources, biotechnology will take the country a long way.

Source:
http://www.biotechblog.org/rss.xml

Scientific innovation: How biotechnology fits into America’s future

America, the name itself conjures an image of prosperity, high standards of living, a staggering economy, flourishing industries, and everything nice and good. But all these nice and good things were not achieved in a day. It took years of hard work and organization to reach this epoch. Most importantly, this is the fruit of years of continuous research and innovations which have helped this country to surge ahead of the rest in all fields. A few prime gifts of this country to the world includes Internet, and many others as the country gears up to continue its quest to remain not only the most powerful economy but technologically also the country should dig into new found mines of biotechnology. Biotechnology uses micro-organisms and the various biological processes to generate commercially viable bioproducts. At some instances, biotechnology is not used commercially but more importantly just to protect our mother nature and create a greener environment.

Early years

Long before the term biotechnology came into existence, it was indigenously used in various food processing processes like making beer, wine, cheese, etc. Other than that it was used in various aspects of agriculture like selection of high yielding crops, use of legumes to fertilize soil, making natural manures, etc. The advent of modern biotechnology took place in the 1970s. The red wave, in which the potential of biotechnology were appreciated in the field of medicine and put to practical use. The medical industry has found a new direction on the shoulders of biotechnology and surely it’s way ahead is shining bright with the newer discoveries and methodologies. The white wave, the last to strike the field is the industrial application of biotechnology.Yet to build a strong wave and flood the industry and economy with its immense potentialities.

1. Advancement in the field of agriculture

America’s farming is highly mechanized. With that, the use of biotechnology has led to production more than sufficing the needs of the country. High yielding, pest and drought resistant, better nutritional value, altered tasting crops have been produced. This has provided the country food security. And surely in future, with more advancements in biotechnology will take the agriculture up the ladders of prosperity.

2. Advancement in the field of medicine

Currently more than 50% of the biotechnology industry is concentrated in the medical field with the prime work force, staggering growth rate, speedy discoveries and millions of dollars pumped into research. This field has truly bloomed to serve the cause of human health. Genome mapping, monoclonal antibodies, synthesis of antibiotics and artificial hormones, gene therapy, rapid diagnostic methods, anti cancer drugs are the result of the meticulous research in this field. All this helped improve the health of the people and indirectly the nation. The National Alzheimer’s Project Act has been passed to control the disease and at the same time develop new drugs to treat it. Though a lot has been achieved, but this field shouldn’t be allowed to stagnate under any circumstances. As newer resistant viruses and bacteria emerge, the medical force should be prepared with the weapons made from biotechnology.

3. Advancement in the field of industrial application

Industries entirely based on biotech seem just round the corner as the potential of this field are being recognized with rapidity. Biodiesel now, generated at a commercial level can do away with the country’s dependence on the oil supplies from the gulf countries. Also it is a greener technology. Biomining is a method in which a solution of bacteria is used for extraction of metals (copper and gold). Bio-oxidation, a method in which bacteria is used to extract metal from their oxidized form. Both the forms yield high extraction rates upto 85-95%. Bioplastics, enzymes and many other products are awaited to be produced at an industrial level. Jatropha has the potential to replace petroleum as fuel. If the wonders of biotechnology are tapped commercially definitely it would contribute to the flourishing economy of the country. Although its contribution to the country’s GDP is meager, already it is one of the fastest growing sectors employing 130305 in 2005, with a turnover of US $51,655 million the same year. Needless to say that America is leading in all aspects of the biotechnology industry and hopefully it will continue to do so.

Last but not the least

Recently, America is facing steep competition from other developing nations like India and China and so the country needs to be on its toes. The current policies of the Barak Obama government are very favorable for extensive research and large amount of investments in the field. The other brighter side of this industry is the employment it is generating which has become particularly very important after the unemployment during and after recession. The upcoming new industries, the health and as well as the agriculture sector depend hugely on the advancements of biotechnology, so extensive research is being undertaken at all levels. The National Institute of Health is instituted for biotechnology training programs. Lastly the future of NASA, America’s prime space agency, also rests on newer biotech products as it aims to sustain life for a prolonged period outside earth. We hope that biotechnology will bloom to the most beautiful and prosperous future of America.

Source:
http://www.biotechblog.org/rss.xml

International Stem Cell Corporation Completes $5 Million Financing and Elects Jim Berglund to the Board of Directors

CARLSBAD, Calif. (March 12, 2012) – International Stem Cell Corporation (OTCBB:ISCO) http://www.internationalstemcell.com, a California-based biotechnology company focused on therapeutic, cosmetic and research products, announced today that it had obtained new capital financing and made important changes in the composition of its Board of Directors to ensure that Independent Directors hold the majority of Board seats.
The financing consists of $5 million in newly issued Series G Convertible Preferred Stock (without warrants), convertible into Common Stock at a conversion price of $0.40/share, the market price of the Company’s Common Stock on the date the offer to purchase was made.  This financing was made by AR Partners LLC, a healthcare investment firm owned by Dr. Andrey Semechkin ISCO’s CEO and Co-Chairman of the Board of Directors.
Concurrently with the closing of this financing, the Company elected to its Board of Directors Dr. James Berglund, co-founder of Enterprise Partners Venture Capital - one of the premier venture capital firms in the field of healthcare technology founded in 1985. Dr. Berglund, with his extensive professional experience, continues as an active participant in the biotech and healthcare industries. Dr. Berglund will replace Kenneth C. Aldrich, co-founder and former CEO of the Company during the period 2008-2009, who is stepping down as ISCO Board of Directors Co-Chairman. Although Mr. Aldrich is retiring from our Board, he will remain as one of ISCO’s largest shareholders and an active consultant to the Board and executive management and will continue to represent the Company as “Chairman Emeritus” in a variety of public and private venues.
According to Mr. Aldrich, “In my view, Dr. Semechkin’s willingness to commit such a significant amount of capital to ISCO at the market price of the Company’s stock on the date of his offer represents a major vote of confidence in ISCO’s future by its most senior executive. We are thankful to Dr. Semechkin for his support that will further advance ISCO’s parthenogenetic stem cell-based therapeutic programs and income generating businesses.”
Having a majority of independent directors on our company’s Board represents an important step in ISCO’s development and in transforming ISCO into a leading public company in the field of regenerative medicine.
“I want to thank Mr. Aldrich for his long-standing dedication and continued involvement in guiding the Company,” said Dr. Semechkin. “This long-term investment, along with the new executive management team recruited over the previous twelve months, will provide ISCO with the necessary economic stability and resources to pursue its goals of consolidating our leadership position and accelerating our therapeutic programs” continued Dr. Semechkin.
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products.  ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). HpSCs avoid ethical issues associated with the use or destruction of viable human embryos.  ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial backgrounds.  This offers the potential to create the first true stem cell bank, UniStemCell™.  ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care.  More information is available at http://www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
Forward-looking Statements
Statements pertaining to anticipated developments and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.
Contacts:
International Stem Cell Corporation
Andrey Semechkin, Co-Chairman and CEO
760-940-6383
Kurt May, President/COO
760-940-6383
Lippert/Heilshorn & Associates 
Don Markley (dmarkley@lhai.com)
310-691-7100

Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss

Researcher Alert: California Stem Cell Agency To Alter How It Administers Grants


Stem cell researchers and institutions throughout the state are likely to be affected by proposed changes – to be discussed online publicly Tuesday – dealing with how the California stem cell agency will handle its $3 billion in grants.

An important online session – open to all interested parties – comes up then, but advance registration is required.

The proposals are wide-ranging and detailed. The nearly 500 recipients of CIRM grants should examine them closely in addition to any persons seriously interested in California stem cell affairs. The changes deal with such subjects as milestones for research grants, indirect costs, travel costs, withholding payments for failure to file a progress report and much, much more.

Here is a link to the main page for all this, which has instructions on how to register for the online session along with links to the changes and their rationale.

(Editor's note: This item was filed from the Rio Sabana in the Darien in Panama when we found a weak Internet cellular link. We are still underway so postings are unlikely between now and later this month.)

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

Essential tremor: what are the treatment options?

Essential tremor is a common neurologic problem. It should be differentiated from secondary causes of tremor and Parkinson disease.

Impact of essential tremor

Essential tremor causes motor dysfunction (e.g. a dentist may have to quit his/her job). However, more importantly, the tremor can have a psychological impact on the patient, especially since it usually gets worse in social situations.

Diagnosis

Essential tremor is a clinical diagnosis. A thorough review of the medical history and medication exposures is a good start. Laboratory and imaging tests may be ordered to rule out a secondary cause.

Treatment

The two first-line agents in drug therapy for essential tremor are:

- nonselective beta-blocker propranolol (Inderal)
- antiepileptic primidone (Mysoline)

They can be used alone or in combination.

Severe, resistant, or atypical cases should be referred to a specialist. Botulinum toxin injection and deep brain stimulation are reserved for resistant tremor or for patients who do not tolerate drug therapy.

Dr. Young from Swedish Medical Center discusses some of the new treatments for essential tremor in this video:

References:

Essential tremor: Choosing the right management plan for your patient. CCJM, 2011.

Posted at Clinical Cases and Images. Stay updated and subscribe, follow us on Twitter and connect on Facebook.


Source:
http://feeds.feedburner.com/CasesBlog

3 million Americans are living with celiac disease

Celiac disease, an immune system reaction to gluten in the diet, is four times as common today as it was 50 years ago. Lack of awareness of celiac could be contributing to a delay of up to 11 years in diagnosis of adults in North America (http://goo.gl/sy778).

This is a very informative and beautifully designed video by the University of Chicago Celiac Disease Center. It looks like an infographic made into video - have a look:

New classification is being proposed for gluten-related disorders: celiac disease; dermatitis herpetiformis; gluten ataxia; wheat allergy; gluten sensitivity. WSJ, 2012.

Recent studies support the existence of the new condition nonceliac gluten sensitivity which is defined as symptoms with negative celiac antibodies and biopsy (http://goo.gl/57IlB).

Key figures:

New nomenclature and classification of gluten-related disorders

Algorithm for the differential diagnosis of gluten-related disorders, including celiac disease, gluten sensitivity and wheat allergy. BMC Medicine 2012.

References:

Celiac disease is different from wheat allergy

Disclaimer: I am an Assistant Professor of Medicine and Pediatrics at University of Chicago.

Posted at Clinical Cases and Images. Stay updated and subscribe, follow us on Twitter and connect on Facebook.


Source:
http://feeds.feedburner.com/CasesBlog

Bench to boardroom and the pipette competition

Last week I attended the Bench to Boardroom event organised by OneNucleus at the Newmarket Racecourse. Under the slogan discover-learn-connect, there were opportunities during the day to explore these themes. We certainly learnt a lot from Prof Sir Christopher Evans, whose keynote speech (the first of the day) ’From bench to billions’ inspired and incited debate, something I have now learnt to expect from him. Described by many as the founding father of the Cambridge biotech cluster, he talked about many things (we’ll be publishing the interview I had with him within the next couple of weeks so keep an eye on the homepage), among them what makes a business successful. The essential ingredients in his view are: a good product, excellent people, an exciting business plan, money (plenty of it!), hard work and luck. It doesn’t look like rocket science but I guess the trick is getting all the elements of the equation right.

Fisher Scientific run a "fast pipette" competition at Bench to Boardroom

There was a also an opportunity to discover that my pipetting skills are still up to scratch when I came second (a position I shared with the gentleman in the picture) in the Fisher pipette competition that Fisher Scientific were running from their stand on the exhibition floor. The challenge was to fill six tubes of different volumes with different amounts of liquid, i.e. two 50ml tubes required 15ml each, two 15ml tubes required 5ml each, etc. I managed to do it in 1 minute 29 and you can just about manage to make out the text in the leader board shown in the picture (in case someone wants proof!), which is quite a feat if we take into consideration that I haven’t done any real chemistry since 2004. Also, in my defence (I should have been first really, after all I was representing the RSC plus there was a bottle of bubbly for the winner), when I did the test I had just arrived and my hands were freezing. In any case, I’m revelling in my success and my prize of Smarties!

The second keynote speaker was Alison Campbell, who told us: ‘There are two Is in innovation’, the second one being for investment, which she referred to as ‘intelligent capital’. Interestingly, she also emphasised the importance of choosing the right people to set up business with. ‘You need a partner, but the right one’, she said, and you have to value the time your partner invests, after all ‘the greatest type of investment is investment of their time’.

There were opportunities to  network during the workshops that were run throughout the day (Deloitte looked at the patent box and Global Regulatory Services covered the NHS, to name just a couple) or on the exhibition floor, which was covered with a range of suppliers, including equipment suppliers, providers of technical services, etc.

To finish it all we were treated to a live show by Dr Hal, who brought chemistry to life with experiments like the exploding ostrich egg, manufacturing liquid oxygen and chemiluminescence. A good time was had by all!

Bibiana Campos Seijo

successful
Digg This  Reddit This  Stumble Now!  Share on Facebook  Bookmark this on Delicious  Share on LinkedIn  Bookmark this on Technorati  Post on Twitter  Google Buzz (aka. Google Reader)  

Source:
http://prospect.rsc.org/blogs/cw/?feed=rss2

Plugging snails into the Matrix

plugging snails into the matrix

Plugging snails into the Matrix © ACS

In the 1999 film The Matrix, a race of sentient machines gets its power by harvesting bioelectricity from farms of plugged in human beings.

While that’s (as far as I know) not yet been realised, a group at Ben-Gurion University in Israel has managed to plug into a snail as a power source.

The team implanted a biofuel cell into a living land snail. The cell is made from carbon nanotube ‘paper’ modified with enzymes that process sugar. As the snail eats, some of the glucose in its food ends up in the fuel cell and generates electricity.

There’s no danger of the machines overthrowing their human masters just yet, though – the maximum power from the snail cell was 7.45µW, so it would take quite a lot of snails to power even a small robot. That said, the aim of these devices is not really to create a new source of renewable power by enslaving armies of snails – more to power tiny implanted medical devices that deliver drugs or monitor diseases.

I just hope they don’t join forces with the cockroaches with fuel cell-powered implants to control their movements.

Phillip Broadwith

Ref: L Halámková et al, J. Am. Chem. Soc., 2012, DOI: 10.1021/ja211714w

Digg This  Reddit This  Stumble Now!  Share on Facebook  Bookmark this on Delicious  Share on LinkedIn  Bookmark this on Technorati  Post on Twitter  Google Buzz (aka. Google Reader)  

Source:
http://prospect.rsc.org/blogs/cw/?feed=rss2

Sherwood Rowland dies aged 84

F. Sherwood Rowland

Sherwood Rowland, died 10 March. © Steve Zylius / University Communications

The sad news has reached us that atmospheric chemist Sherwood Rowland died on Saturday 10 March, aged 84, from complications related to Parkinson’s disease. Best known for his discovery, along with post-doc Mario Molina, that chlorofluorocarbons (CFCs) destroy ozone nearly 40 years ago, Rowland campaigned for a ban on the use of  the widely used and lucrative CFCs.

In 1987, some years after the original discovery of the the action of CFCs, and following evidence of their work above the Antarctic to cause a hole in the ozone layer, CFCs were finally banned from sale. ‘His publicising the adverse effects of release of CFCs in the 1970s did not endear him to industry, but eventually led to his Nobel Prize, which he shared with Mario Molina and Paul Crutzen,’ said RSC President David Phillips in a statement today. ‘In the early stages of his research on CFCs, he and his students used to travel the world taking air samples – I have some photographs of him doing just that in the grounds of the Vatican in Rome in 1982 where he and I were taking part in a Discussion Meeting of the Pontifical Academy of Sciences.’

Rowland did not rest after his work on CFCs and as well as research he campaigned against other harmful air pollutants. In 2009 Rowland joined with other Nobel Prize winners to urge US President Barack Obama to increase funding for energy research and development. ‘The most important molecule involved in global warming is carbon dioxide,’ Rowland told Chemistry World at the time. ‘What we are looking for is energy solutions that are advanced and that can last for centuries or more, and chemists will need to be working on these things for an extended period of time.’

Frank Sherwood Rowland, known as Sherry, was born on June 28, 1927 in Delaware, Ohio. After gaining his PhD at the University of Chicago with physical chemist Willard Libby, Rowland originally worked as a nuclear chemist and was a founding faculty member of the University of California, Irvine campus, which was to be his home from 1964. ‘He was a major force in atmospheric chemistry, and, along with his family, he will be greatly missed by all of his colleagues too,’ Phillips said.

Rowland is survived by his wife Joan, daughter Ingrid, son Jeffrey and two grandchildren.

Laura Howes

Digg This  Reddit This  Stumble Now!  Share on Facebook  Bookmark this on Delicious  Share on LinkedIn  Bookmark this on Technorati  Post on Twitter  Google Buzz (aka. Google Reader)  

Source:
http://prospect.rsc.org/blogs/cw/?feed=rss2